Medicine and Dentistry
Chronic Thromboembolic Pulmonary Hypertension
100%
Pulmonary Hypertension
77%
Venous Thromboembolism
46%
Splenectomy
28%
Myeloproliferative Disorder
28%
Anticoagulant Therapy
28%
Acute Pulmonary Embolism
25%
Hemodynamic
24%
Bleeding
23%
Atrial Septal Defect
23%
Kyphoscoliosis
23%
Antiphospholipid Syndrome
23%
Thrombocytopenia
23%
Cardiovascular Disease
23%
Anemia
23%
Idiopathic Thrombocytopenic Purpura
23%
Vaccination Coverage
23%
Primary Immunodeficiency
23%
Vaccine Hesitancy
23%
Dasatinib
23%
COVID-19 Vaccination
23%
Angioplasty
23%
Demography
23%
Lung Vascular Resistance
19%
Malignant Neoplasm
19%
Major Bleeding
18%
Cardiac Catheterization
18%
Brain Natriuretic Peptide
14%
Platelet
14%
Lung Artery Pressure
13%
Pulmonary Embolism
13%
Antiphospholipid Antibody
11%
Hazard Ratio
10%
Dyspnea
9%
Cardiovascular System
8%
Systolic Blood Pressure
8%
Oxygen Therapy
7%
Ambrisentan
7%
Echocardiography
7%
Heart Left Ventricle Ejection Fraction
7%
Pulmonary Artery Occlusion Pressure
7%
Prevalence
5%
COVID-19
5%
Heart Right Ventricle Failure
5%
Endarterectomy
5%
Autoimmune Disease
5%
Major Surgery
5%
Thrombocyte Transfusion
5%
Endocardium
5%
Stillbirth
5%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Thromboembolic Pulmonary Hypertension
57%
Venous Thromboembolism
46%
Pulmonary Hypertension
46%
Malignant Neoplasm
26%
Anticoagulant Agent
23%
Kyphoscoliosis
23%
Bleeding
23%
Anemia
23%
Cardiovascular Disease
23%
Brain Natriuretic Peptide
10%
Survival Rate
9%
Ambrisentan
7%
Persistent Pulmonary Hypertension
5%
Obstruction
5%
Hospital Mortality
5%
Functional Status
5%